Trademarkia Logo

Canada

C$
MISCELLANEOUS DESIGN
FORMALIZED

on 16 May 2024

TM5 Status

LIVE/APPLICATION/ Awaiting Examination

Your application is awaiting examination.

Last Applicant/ Owned by

PFIZER INC.

66 Hudson Boulevard EastNew York, NY 10001-2192

US

Serial Number

2327781 filed on 16th May 2024

Correspondent Address

TORYS LLP

SUITE 300079 WELLINGTON ST. W.BOX 270, TD CENTRETORONTO

ONTARIO

CA

M5K1N2

MISCELLANEOUS DESIGN

Trademark usage description

pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy a Read More

Vienna Information


26 . 3 . 23

Lines or bands forming an angle -- Note: Including chevrons and arrowheads formed by lines or bands.Lignes ou bandes formant un angle -- Note: Y compris les chevrons et les pointes de flèches formées par des lignes ou des bandes.

26 . 1 . 1

CirclesCercles

26 . 1 . 4

Two circles, two ellipses, one inside the otherDeux cercles, deux ellipses, l'un dans l'autre

26 . 1 . 18

Circles or ellipses containing one or more lettersCercles ou ellipses contenant une ou plusieurs lettres

26 . 1 . 19

Circles or ellipses with inscriptions projecting beyond the circumferenceCercles ou ellipses avec inscriptions débordant la circonférence

26 . 1 . 24

Circles or ellipses with dark surfaces or parts of surfacesCercles ou ellipses avec surface ou partie de la surface foncée

26 . 1 . 26

Circles or ellipses with cutout areasCercles ou ellipses avec des zones découpées

27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 21

One letterUne lettre

Classification Information


Class [005]
Pharmaceutical preparations for the treatment of neurodegenerative, nerve, neuromuscular and brain diseases and disorders, namely muscular dystrophy and ALS; Pharmaceutical preparations for the treatment of the central nervous system, namely brain diseases and central nervous system movement disorders; Pharmaceutical preparations for the treatment of cardiovascular, gastrointestinal and blood diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases and disorders, namely rheumatoid arthritis, lupus, alopecia, ulcerative colitis and Crohn's disease; Pharmaceutical preparations for the treatment of hypertension, menopause symptoms, obesity, stroke, arthritis, migraine, pain and endometriosis; Pharmaceutical preparations for the treatment of cancer; Anti-infectives, anti-inflammatories, anti-fungal and anti-viral agents; Pharmaceutical preparations for the treatment of kidney and liver diseases and disorders; Pharmaceutical preparations for the treatment of bone growth disorders; Pharmaceutical preparations for the treatment of diseases and disorders of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders, Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely cachexia, diabetes, hypoglycemia, obesity, sickle cell disease, non-alcoholic steatohepatitis (NASH) and anemia; Pharmaceutical preparations for the treatment of skin and dermatological diseases and conditions, namely eczema, atopic dermatitis, psoriasis and vitiligo; Human vaccines;


Classification kind code

12

Mark Details


Serial Number

2327781

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 287
on 30th May 2024
Pre-Assessment Letter Sent
Submitted for opposition 30
on 16th May 2024
Filed
Submitted for opposition 1
on 16th May 2024
Created
Submitted for opposition 31
on 16th May 2024
Formalized